Robert Brunell

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Paul M. Ridker, James H. Revkin, Pierre Amarenco et al. · New England Journal of Medicine · 2017 · 630 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee

Marie‐Pierre Hellio Le Graverand, R. Clemmer, Patricia Redifer et al. · Annals of the Rheumatic Diseases · 2012 · 136 citations

Medicine, Orthopaedic Surgery, Pharmacology +12

Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials

Paul M. Ridker, Pierre Amarenco, Robert Brunell et al. · American Heart Journal · 2016 · 64 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Considerations when designing a disease-modifying osteoarthritis drug (DMOAD) trial using radiography

Marie‐Pierre Hellio Le Graverand, R. Clemmer, Robert Brunell et al. · Seminars in Arthritis and Rheumatism · 2013 · 19 citations

Medicine, Orthopaedic Surgery, Pharmacotherapy +9

Meta-analysis of cardiac safety with aripiprazole

Dušan Kostić, A.R. Saha, Robert Brunell et al. · Schizophrenia Research · 2003 · 11 citations

Medicine, Pharmacology, Pharmacotherapy +12